

DAFTAR PUSTAKA

1. Bittel, D. C. & Butler, M. G. Prader – Willi syndrome : clinical genetics , cytogenetics and molecular biology to be imprinted and located in the chromosome. **7**, 1–20 (2005).
2. Genetics, P. Prader – Willi syndrome. 3–13 (2009)
3. Butler, M. G., Manzardo, A. M., Heinemann, J., Loker, C. & Loker, J. Original Research Article Causes of death in Prader-Willi syndrome : Prader-Willi Syndrome Association (USA) 40-year mortality survey. 1–8 (2016)
4. Fintini, D., Bocchini, S., Carducci, C. & Grugni, G. Prader – Willi syndrome : clinical problems in transition from pediatric to adult care. 49–57 (2016).
5. Mccann, K. L. & Baserga, S. J. Long Noncoding RNAs as Sinks in Prader-Willi Syndrome. *Mol. Cell* **4**, 155–157 (2012).
6. Puiu, M. *et al.* Prader – Willi Syndrome and diagnostic protocols : a preliminary study in Romania Sindrom. 18, 15–22 (2010).
7. Scheermeyer, E. *et al.* PT. *Growth Horm. IGF Res.* (2017)
8. Cassidy, S. B., Schwartz, S., Miller, J. L. & Driscoll, D. J. genetest review Prader-Willi syndrome GeneTest review. 14, (2012).
9. Wollmann, H. A., Schultz, U. & Grauer, M. L. Reference values for height and weight in Prader-Willi syndrome based on 315 patients. 634–642 (1998).
10. Brambilla, P., Bosio, G. C., Manzoni, P., Pietrobelli, A. & Beccaria, L. Peculiar body composition in patients with Prader-Labhart. (2018).
11. Words, K. & Background, S. Is There Growth Hormone Deficiency in Prader-Willi Syndrome ? 53, 44–52 (2000).
12. Mu, J., Blichfeldt, S., Rosenborg, M., Brismar, T. & Hagen, L. Growth hormone treatment of children with Prader-Willi syndrome affects linear growth and body composition favourably. 28–31 (1998).
13. Goldstone, A. P., Holland, A. J., Hauffa, B. P. & Tauber, M. Recommendations for the Diagnosis and Management of Prader-Willi

Syndrome. 4183–4197 (2008) d

14. Miller, J. L. *et al.* Nutritional Phases in Prader – Willi Syndrome. 1040–1049 (2012)
15. IDAI. KONSENSUS IKATAN DOKTER ANAK INDONESIA: Diagnosis dan Tata laksana Sindrom Metabolik pada Anak dan Remaja. *Idai (Ikatan Dr. Anak Indones.* 1, 35 (2014).
16. Brambilla, P. *et al.* Metabolic syndrome in children with Prader-Willi syndrome: The effect of obesity. *Nutr. Metab. Cardiovasc. Dis.* **21**, 269–276 (2011).
17. Daniels S & S, C. Lipid disorders in children and adolescents. *Pediatr. Endocrinol.* 1015 (2014).
18. Stephen Cook & Rae Ellen W Kavey. Dyslipidemia and Pediatric Obesity. *Pediatr Clin North Am*, 1363–1373 (2011).
19. Yang, A., Kim, J., Cho, S. Y. & Jin, D. K. Prevalence and risk factors for type 2 diabetes mellitus with Prader-Willi syndrome: A single center experience. *Orphanet J. Rare Dis.* 12, 1–9 (2017).
20. Einfeld, S. L., Kavanagh, S. J., Evans, E. J., Tonge, B. J. & Taffe, J. Mortality in Prader-Willi Syndrome. 111, 193–198 (2006).
21. Patel, S. *et al.* Characteristics of cardiac and vascular structure and function in Prader – Willi syndrome. 771–777 (2007)
22. Colao, A., Marzullo, P. & Somma, C. Di. Growth hormone and the heart. 137–154 (2001).
23. Evans, L. M., Davies, J. S., Goodfellow, J., Rees, J. A. E. & Scanlon, M. F. Endothelial dysfunction in hypopituitary adults with growth hormone deficiency. 457–464 (1999).
24. Bisi, G. *et al.* Acute cardiovascular and hormonal effects of GH and hexarelin , a synthetic GH-releasing peptide , in humans. 266–272 (1999).
25. Reus, L. *et al.* Neuroscience and Biobehavioral Reviews Motor problems in Prader – Willi syndrome : A systematic review on body composition and neuromuscular functioning. *Neurosci. Biobehav. Rev.* 35, 956–969 (2011).
26. Elizabeth, Q. & Children, H. Prader-Willi syndrome after age 15. 181–186

(1981).

27. Holm, V. A. & Luurnen, E. L. Prader-Willi Syndrome and Scoliosis. (1981).
28. Miller, J. L. & Tan, M. Dietary Management for Adolescents with Prader–Willi Syndrome. *Adolesc. Health. Med. Ther.* 11, 113–118 (2020).
29. Castner, D. M., Tucker, J. M., Wilson, K. S. & Rubin, D. A. Patterns of habitual physical activity in youth with and without Prader-Willi Syndrome. *Res. Dev. Disabil.* 35, 3081–3088 (2014).
30. Crinò, A., Fintini, D., Bocchini, S. & Grugni, G. Obesity management in Prader–Willi syndrome: Current perspectives. *Diabetes, Metab. Syndr. Obes. Targets Ther.* 11, 579–593 (2018).
31. Butler, M. G., Bittel, D. C., Kibiryeva, N., Talebizadeh, Z. & Thompson, T. Behavioral Differences among Subjects with Prader-Willi Syndrome and Type I or Type II Deletion and Maternal Disomy. *Pediatrics*, 565–573 (2004).
32. Akefeldt, A. & Gillberg, C. Behavior and Personality Characteristics of Children and Young Adults With Prader-Willi Syndrome : A Controlled Study. 38, 761–769 (1994).
33. Borsel, J. Van & Tetnowski, J. A. Fluency disorders in genetic syndromes. 32, 279–296 (2007).
34. Soetjningsih. Tumbuh kembang anak. in *Jakarta: EGC* (Jakarta: EGC, 1995).
35. Flynn JT *et al.* Clinical practice guideline for screening and management of high blood pressure in children and adolescents. *Pediatrics* 140 (2017).
36. UKK Nutrisi dan Penyakit Metabolik IDAI. *Diagnosis, Tata Laksana dan Pencegahan Obesitas pada Anak dan Remaja.* (2014).
37. Sjarif, D. *et al.* Diagnosis, Tata Laksana dan Pencegahan Obesitas pada Anak dan Remaja. *Jakarta Unit Kerja Koord. Nutr. dan Penyakit Metab. Ikat. Dr. Anak Indones.* (2014).
38. UKK Endokrinologi pada Anak dan Remaja, IDAI & World Diabetes Federation. *World Diabetes Federation. Konsensus Nasional Pengelolaan Diabetes Mellitus Tipe 2.* (2015).

39. Burman, P., Ritzen, E. M. & Lindgren, A. C. Endocrine dysfunction in Prader-Willi syndrome: a review with special reference to GH. *Endocr. Rev.* 22, 787–799 (2001).
40. Butler, M. G. *et al.* Growth charts for non-growth hormone treated prader-willi syndrome. *Pediatrics*, 126–135 (2015).
41. Carrel, A. L., Myers, S. E., Whitman, B. Y. & Allen, D. B. Benefits of long-term GH therapy in Prader-Willi Syndrome: A 4-year study. *J. Clin. Endocrinol. Metab.* 87, 1581–1585 (2002).
42. Eiholzer, U. & L'Allemand, D. Growth hormone normalises height, prediction of final height and hand length in children with Prader-Willi syndrome after 4 years of therapy. *Horm. Res.* 53, 185–192 (2000).
43. Butler, M. G. Management of obesity in Prader-Willi syndrome. *Nat. Clin. Pract. Endocrinol. Metab.* 2, 592–593 (2006).
44. Vozmediano, C., Rivera, F., López-Gómez Manuel, J. & Hernández, D. Risk Factors for Renal Failure in Patients with Lupus Nephritis: Data from the Spanish Registry of Glomerulonephritis. *Nephron Extra*, 269–277 (2012).
45. Scheimann, A. O., Butler, M. G., Gourash, L., Cuffari, C. & Klish, W. Critical analysis of bariatric procedures in Prader-Willi syndrome. *J. Pediatr. Gastroenterol. Nutr.* 46, 80–83 (2008).
46. De Lind Van Wijngaarden, R. F. A., Cianflone, K., Gao, Y., Leunissen, R. W. J. & Hokken-Koelega, A. C. S. Cardiovascular and metabolic risk profile and acylation-stimulating protein levels in children with Prader-Willi syndrome and effects of growth hormone treatment. *J. Clin. Endocrinol. Metab.* 95, 1758–1766 (2010).
47. Donaghue KC *et al.* Microvascular and macrovascular complications in children and adolescents. *Pediatr Diabetes* 15, 257–269. (2014).
48. Boyraz M *et al.* Non-alcoholic fatty liver disease in obese children and the relationship between metabolik syndrome criteria. *Obes Res Clin Pr.* 28, 356–363 (2014).